John Patton
Director of Investor Relations and Communication
Replay available
Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call
Oncolytics Biotech Inc. (NASDAQ: ONCY) Q2 2024 earnings conference call, held 2024-08-01. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Wayne Pisano
Chair of the Board of Directors and Interim CEO
Dr. Tom Heinemann
Chief Medical Officer
Christophe Degois
Vice President, Business Development
Kirk Look
Chief Financial Officer
John Newman
Analyst, Canaccord
Samit Roy
Analyst, Jones Research
Michael Kumerwick
Analyst, Maxim Group
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Oncolytics Biotech Inc..
Replay transcript excerpt
WEBVTT 00:00:00.009 -- 00:00:05.532 Good afternoon and welcome to Oncolytics Biotech's second quarter 2024 00:00:05.532 -- 00:00:10.475 conference call. All participants are now in a listen-only mode. 00:00:10.475 -- 00:00:14.217 There will be a question and answer session at the end of this call. 00:00:14.217 -- 00:00:19.160 Please be advised that this call is being recorded at the company's request. 00:00:19.160 -- 00:00:24.343 I would now like to turn the call over to Jan Patton, Director of Investor Relations 00:00:24.343 -- 00:00:25.984 and Communication. 00:00:25.984 -- 00:00:28.424 Please go ahead. 00:00:30.998 -- 00:00:32.039 Thank you, Operator. 00:00:32.039 -- 00:00:36.202 Earlier today, OnClinics issued a press release providing recent operational highlights 00:00:36.202 -- 00:00:38.103 and financial results for the second quarter of 2024. 00:00:38.103 -- 00:00:39.664 A 00:00:39.664 -- 00:00:45.108 replay of today's call will be available on the event section of the OnClinics website. 00:00:45.108 -- 00:00:48.631 And after remarks from company management, we will open the call for Q&A. 00:00:48.631 -- 00:00:52.493 As a reminder, various remarks made during this call contain certain forward-looking 00:00:52.493 -- 00:00:56.776 statements relating to the company's business prospects and the development and commercialization 00:00:56.776 -- 00:01:00.587 of Pella Reader App. including statements regarding the company's mission, strategy, 00:01:00.587 -- 00:01:05.248 and milestones, the company's belief as to the potential and mechanism of action of Pell 00:01:05.248 -- 00:01:09.608 Rear Up as a cancer therapeutic, our belief that we are positioned to execute on our 00:01:09.608 -- 00:01:14.289 key priorities and reach multiple milestones throughout the second ...